Biotechnology - Licensing, Regulation

Filter

Current filters:

LicensingRegulation

Popular Filters

Celgene exercises option for Agios Pharma’s AG-221

Celgene exercises option for Agios Pharma’s AG-221

17-06-2014

Metabolism specialist Agios Pharmaceuticals says that its partner, biotech major Celgene Corp, has exercised…

AG-221Agios PharmaceuticalsBiotechnologyCelgeneLicensingOncologyRegulationResearchUSA

Takeda to withdraw NDA as Omontys pact with Affymax ends

Takeda to withdraw NDA as Omontys pact with Affymax ends

15-06-2014

USA-based Affymax and Japan's Takeda Pharmaceutical revealed on Friday that they have terminated their…

AffymaxBiotechnologyLicensingOmontysOncologyRegulationTakeda Pharmaceutical

RedHill Biopharma views regulatory pathway for RHB-101 in CHF and hypertension

29-05-2013

Emerging Israeli biopharma company RedHill Biopharma (TASE: RDHL) says that it recently concluded a positive…

BiotechnologyCardio-vascularCarvedilolLicensingPharmaceuticalRedHill BiopharmaRegulationResearchRHB-101

Bristol-Myers gets added indication from US FDA for Sustiva; signs second deal with Ambrx

06-05-2013

US pharma major Bristol-Myers Squibb (NYSE: BMY) says that the US Food and Drug Administration has approved…

AmbrxAnti-viralsBiotechnologyBristol-Myers SquibbCardio-vascularDiabetesLicensingNorth AmericaPharmaceuticalRegulationSustiva

Isis Pharma/GlaxoSmithKline's ISIS-TTR Rx gains US fast-track designation

14-12-2012

In what has been a busy newsflow few days for USA-based Isis Pharmaceutical (Nasdaq: ISIS), the company…

BiotechnologyGlaxoSmithKlineIsis PharmaceuticalsISIS-TTR.RXLicensingNorth AmericaPharmaceuticalRare diseasesRegulation

VentiRx collaborates with Celgene on cancer drug candidate; pomalidomide update

05-10-2012

VentiRx Pharmaceuticals, a privately held US biopharmaceutical company dedicated to the development of…

BiotechnologyCelgeneLicensingNorth AmericaOncologyPharmaceuticalpomalidomideRegulationVentiRx PharmaceuticalsVTX-2337

Back to top